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“Designer drugs” is the term 
used to describe drugs that 
are synthetically derived from 
federally controlled substances 
or naturally derived to create 
new psychoactive agents. The 
molecular structures of exist-
ing drugs are slightly modi!ed 
and produced in clandestine 
laboratories for illicit, recre-
ational use. The intent of de-
signer drugs is to circumvent 
the law and test the bounds 
of new chemicals, frequently 
with deadly results. Part of 
the problem is that these new 
products keep changing. Illicit 
drug makers use this tactic 
to stay one step ahead of law 
enforcement agencies. If law 
enforcement identi!es a new 
compound and classi!es it as 
an illegal drug, then clandes-
tine laboratories react by alter-
ing the composition slightly in 
order to produce a new, tech-
nically legal, drug. 
Banning these substances is a 
time-consuming administra-
tive and scienti!c process that 
can take months to accomplish 
for each drug. The U.S. Drug 
Enforcement Agency (DEA) 
has recently banned some 
An Iowa teenager shot and 
killed himself after su"ering a 
panic attack. A university bas-
ketball player collapsed while 
participating in a preseason 
workout and later died. The 
son of a physician slit his own 
throat, and three days later 
shot and killed himself after 
su"ering continuous halluci-
nations. An 11-year-old boy 
died after hanging himself, 
and a woman attacked and 
killed her sleeping mother 
with a machete. What do all 
of these tragic events have in 
common? They were all trig-
gered by the use of “designer 
drugs.” These are just a sample 
of the growing number of hor-
rible tragedies that have oc-
curred because of the use of 
these agents.  
Playing with the Devil:
Designer Drugs and its Dangers
Nancy Bonthius, PharmD,  University of Iowa Children’s Hospital
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compounds, but they have 
identi!ed 60 new synthetic 
compounds just in the last two 
years that are generally legal. 
To date, there are more than 
250 di"erent compounds that 




Designer drugs are sold in 
small packages in head shops, 
convenience stores, gas sta-
tions, and all over the Internet. 
Drug makers bypass current 
laws by placing the phrase 
“not for human consumption” 
on the labels, which is code 
language meant to imply the 
opposite. These psychoactive 
agents are frequently legal to 
possess, easy to obtain, heavily 
marketed as producing “legal 
highs” similar to illegal drugs, 
and are perceived to be “safer.” 
Pop culture also plays a role 
in the increased use of these 
drugs. For example, teen pop 
idol Miley Cyrus and rappers 
Kanye West and Lil Wayne 
have all made reference to the 
designer drug “Molly,” which is 
a newer analog of the stimu-
lant ecstasy. Miley Cyrus ad-
mitted to making reference to 
this drug in her new song, “We 
Can’t Stop.” 
An urgent need exists for 
health care providers world-
wide to be familiar with the 
adverse e"ects of these novel 
psychoactive designer drugs. 
The goal of this article is to de-
scribe the pharmacology, clini-
cal e"ects, and treatment of 
two important classes of these 
psychoactive designer drugs. 
This article will discuss syn-
thetic cathinones (“Bath Salts”) 




This category of designer 
drugs has nothing to do with 
the bath salts used as a bath 
additive. Instead, this inno-
cent looking name is the term 
given to a category of com-
pounds that mimic certain 
illicit drugs, like cocaine, ec-
stasy, and methamphetamine. 
Cathinone is a naturally oc-
curring beta-ketone amphet-
amine analogue found in the 
leaves of the Khat (Catha edulis) 
plant. Its euphoric e"ects were 
!rst described 1,000 years 
ago. Synthetic cathinones are 
newer derivatives of this com-
pound. The key ingredients 
that have most often been 
used to make “bath salts” are 
the synthetic compounds 
MDPV (3,4-methylenedioxypy-
rovalerone), mephedrone, 
pyrovalerone, and methylone. 
Many other ingredients have 
also been used in addition 
to, or in place of, these com-
pounds. For instance, ex-
tremely high levels of ca"eine 
have been found in many of 
the “bath salts.” In 2011, the 
DEA classi!ed the three most 
common chemicals used to 
make “bath salts” as Schedule 
I controlled substances. 
Unfortunately, they are still 
easily obtained as illegal sub-
stances and as newly modi!ed 
“legal” substances. 
These products are given 
innocent-looking and enticing 
names to lure consumers and 
to disguise its true identities. 
They are sold as a !ne white 
powder and are usually taken 
by nasal insu#ation, oral in-
gestion, intravenous/intramus-
cular injection, or rectal inser-
tion.  Based on information 
collected from the increased 
numbers of calls to poison 
control centers, young men ac-
count for approximately 70% 
of bath salt users. Roughly 18% 
of users are less than 19 years 
old, and its use is highest in the 
20-29-year-old range (43%).   
Playing with the Devil
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Common Names for 
Synthetic Cathinones





Bath Salts Meow Meow
Pure Ivory White Knight
Plant Food White Dove 
Red Rocket Purple Wave
Vanilla Sky Lunar Wave
Ivory Wave Ocean Burst
Cloud Nine Ocean Snow
Pharmacology
and E!ects
Similar to other psychomotor 
stimulants, these agents target 
plasma membrane transport-
ers for dopamine, norepineph-
rine, and serotonin. Users of 
synthetic cathinones describe 
euphoria, increased energy, 
heightened alertness, talk-
ativeness, and increased libido, 
with e"ects typically lasting 
two to eight hours. Users 
frequently describe a com-
pulsion to repeatedly redose 
to prolong the drug’s e"ect, 
with sessions lasting several 
hours to several days. Like am-
phetamines, these drugs are 
capable of inducing tolerance, 
addiction, and dependence.  
Many recent reports and 
!rst-hand accounts by physi-
cians, drug counselors, and 
law enforcement o$cers de-
scribe severely aggressive and 
psychotic behavior by people 
who have used bath salts. 
Often this aggressive behavior 
is coupled with phenomenal 
physical strength, similar to 
that seen in phencyclidine 
(PCP) intoxication. Reports of 
self-mutilation, suicide, and 
persistent paranoid psychosis 
are becoming common across 
the U.S. Interestingly, users 
themselves describe persis-
tent paresthesias and mood 
changes lasting from days to 
weeks after using these drugs.
Physical signs of synthetic 
cathinones intoxication are 
consistent with sympatho-




ior, psychosis, and seizures. In 
addition, hyponatremia, myo-
cardial infarction, myocarditis, 
rhabdomyolysis, stroke, and 
death have been reported. The 
most commonly reported ad-
verse symptoms include head-
ache, chest pain, palpitations, 
paranoia, insomnia, tremors, 
trismus (clenching of the jaw), 
and bruxism (grinding of the 
teeth). Studies have demon-
strated long-term neuronal 
toxic e"ects of these drugs, 
similar to those seen with 
methamphetamine.
Detection/Treatment
Currently none of the synthetic 
cathinones are detected on 
routine urine drug screening 
for amphetamines. However, 
they may cause a false posi-
tive methamphetamine result. 
Blood and urine specimens can 
be analyzed by gas and liquid 
chromatography and mass 
spectrometry, but these assays 
have not yet been accepted 
into routine clinical practice, 
thus are unlikely to give timely 
results.  
No speci!c antidote exists, 
so treatment of exposures to 
these drugs is primarily sup-
portive. Given the similarities 
to amphetamines and cocaine, 
similar management strategies 
based on treating the sympa-
thomimetic e"ects are useful. 
Sympathomimetic toxidrome 
symptoms, including tachy-
cardia, agitation, psychosis, 
hypertension, and seizures, 
should be treated with ben-
zodiazepines. High doses of 
benzodiazepines may be nec-
essary to sedate these patients 
e"ectively. Persistent hyper-
tension can be treated with 
vasodilators (i.e., nitroglycerin 
or sodium nitroprusside). Beta 
blockers should be avoided in 
these patients, due to potential 
hypertension exacerbation 
that may result from unop-
posed alpha-adrenergic stimu-
lation. Hyperthermia should 
be treated with aggressive 
cooling. In the case of severe 
psychiatric symptoms, proper 
restraints should be used to 
Playing with the Devil
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prevent harm to self or others. 
The use of antipsychotic medi-
cations to treat psychosis may 
decrease the seizure threshold, 
placing the patient at an even 
greater risk of seizures. When 
appropriate, physicians should 
test for rhabdomyolysis, he-
molysis, and coagulopathies. 
Patients should be closely 
monitored until resolution of 




Synthetic cannabinoids are 
not structurally similar to tet-
rahydrocannabinol (THC), the 
active ingredient in marijuana. 
However, they are agonists of 
the cannabinoid receptors (CB1 
and CB2). Synthetic cannabi-
noids are also referred to as 
synthetic marijuana or Herbal 
Marijuana Alternatives (HMAs). 
These products are sold as 
alternatives to marijuana, be-
cause they provide similar ef-
fects but are not detectable by 
traditional marijuana screening 
methods. Synthetic cannabi-
noids were originally designed 
in the 1960s by scientists who 
were searching for cannabi-
noid receptor agonists that 
had the same analgesic and 
anti-in%ammatory properties 
of THC, but without the psy-
chotropic e"ects. These agents 
are now best described as 
herbal blends adulterated with 
synthetic cannabinoid com-
pounds. These blends often 
contain 10 or more di"erent 
herbal additives, each of which 
is di$cult or impossible to 
identify. Additionally, hundreds 
of di"erent synthetic canna-
binoid compounds could be 
incorporated into HMAs, mak-
ing them extremely di$cult to 
control. The most frequently 
identi!ed synthetic cannabi-
noid compounds present in 
HMAs are JWH-018, JWH-073, 
JWH-200, CP 47-497, and CP 
47-497C8. The compound 
JWH-018 has a much greater 
a$nity for cannabinoid recep-
tors (four times higher for CB1 
and 10 times higher for CB2), 
than does THC. This greater 
receptor a$nity may partly 
explain the higher number of 
adverse e"ects caused by syn-
thetic cannabinoids, compared 
to THC. Even more worrisome 
is the fact that the synthetic 
cannabinoid HU-210 is 100-800 
times more potent than THC.
In 2011, the DEA classi!ed the 
!ve most common chemi-
cals used to make HMAs as 
Schedule I controlled sub-
stances. Unfortunately, they 
are still easily obtained as il-
legal substances and as newly 
modi!ed “legal” substances 
with marketing claiming 
that they contain no banned 
substances. 
These drugs are given enticing 
names and %ashy packaging 
that usually state such claims 
as “legal high” or “herbal high.” 
These drugs are typically sold 
in small, silvery plastic bags 
of dried leaves and marketed 
as incense or potpourri. The 
actual contents are rarely 
listed on the packaging, and 
brand names and ingredients 
vary widely. Although these 
products are usually smoked, 
some users make them into 
tea.  Much like bath salts, data 
gathered by poison control 
centers found that young men 
account for approximately 
75% of synthetic cannabinoid 
users. Almost 50% of users 
are 13-19-years-old, and most 
of the remainder of users are 
20-29-year-olds. 
Common Names for 
Synthetic Marijuana
K2 Spice Diamond
K3  Clover Spring
Zen Red Merkury
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1. My profession is:
a. R  Family physician
b. R  Pediatrician
c. R  Physician, other specialty:
          ____________________
d. R +HDOWKFDUHRI¿FHPDQDJHU
e. R  Nurse 
f. R  Nurse practitioner 
J R  Nurse, public health
h. R  Physician assistant
i. R  Dietitian 
j.  R 3V\FKRORJLVW
k. R  HeadStart provider
l. R  School nurse
m. R  Social worker
n. R  Teacher or other educator
o. R  Other: 
  ________________________
2. Topics that interest me Most Some Least
  a. R  Well-child care
  b. R+HDOWKLVVXHV&KLOGUHQELUWKWRDJH\HDUV
  c. R+HDWKLVVXHV&KLOGUHQDJHWR\HDUV
  d. R+HDOWKLVVXHV$GROHVFHQWVDJHWR\HDUV
  e. R  Health issues: Children with special needs
  f. R  Health issues: Family
JR  Preventive health care
  h. R  Updates: Recommended clinical protocols 
  i. R8SGDWHV6WDWHDQGIHGHUDOSURJUDPV
  j. R  Referral information: Community resources
  k. R  Care coordination
  l. R  Handouts I can provide to families
  m. R7RSLFVSHFL¿FFRGLQJDQGELOOLQJLQIRUPDWLRQ
$GGLWLRQDOFRPPHQWVRUVXJJHVWLRQVRQQHZVOHWWHUFRQWHQW
3.  I would like each issue of this newsletter to: Always Sometimes Never
  a. R)RFXVRQVLQJOHWRSLF
  b. R&RYHUDUDQJHRIWRSLFV
  c. R+DYHIHZHUDUWLFOHVRIJUHDWHUGHSWK
  d. R  Have more short articles with references on 
  KRZWR¿QGPRUHLQIRUPDWLRQ
  e. R  Provide information in a more clinical way
4.  When the EPSDT Care for Kids Newsletter comes, I usually (please check all that apply):
a. R  Read all of it
b. R  Read some articles
c. R  Scan the headlines
d. R  Look for the handouts
e. R  Put it aside to read later 
f. R  Route the newsletter to others 
  in my workplace
J R  Share it with families
h. R  Talk about it with others
i. R  File it  for future reference 
j. R  File some articles for future 
  reference
5. In our workplace, the people most likely to read this newsletter are (please check all that apply):
a. R  Family physician
b. R  Pediatrician
c. R  Physician, other specialty:
          ____________________
d. R +HDOWKFDUHRI¿FHPDQDJHU
e. R  Nurse 
f. R  Nurse practitioner 
J R  Nurse, public health
h. R  Physician assistant
i. R  Dietitian 
j.  R 3V\FKRORJLVW
k. R  Public health nurse
l. R  Head Start provider
m. R  School nurse
n. R  Social worker
o. R  Teacher or other educator
p. R Other:
  ______________________
2014 Early & Periodic Screening, Diagnosis, and Treatment (EPSDT) 
Care for Kids Newsletter Survey
Please assist us in making the EPSDT newsletter more valuable to you by !lling out the postage-paid survey below. 
Mailing instructions are on the reverse side. Thank you.




a.  ____% Children 













a. R  Private practice
b. R  Hospital-based service
c. R  County health department
d. R  Child Health Specialty Clinic  
e. R  School
f. R  Child care provider




b. R  Via email link to online newsletter
c. R  Twice per year                        
d. R  Three times per year                    
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The pharmacologic e"ects of 
HMAs are likely due to both 
the synthetic cannabinoids 
and the herbal ingredients. 
Many herbs have been identi-
!ed in these products, but 
there is very little medical 
information available to 
guide health care profession-
als regarding its e"ects and 
toxicities.  Additionally, the 
wide variety of synthetic can-
nabinoids present in these 
products makes it even more 
di$cult to predict the symp-
toms and outcomes for spe-
ci!c patients. Typically, after 
use, there is a rapid onset 
of e"ects that last between 
one-half and two hours. The 
desired e"ect of HMAs is 
euphoria.  However, many 
users report that their experi-
ences with these drugs are 
not pleasant and are unlike 
their experiences with THC. 
Drug therapists in addiction 
centers report that users uni-
versally state that the e"ects 
were extremely unpleasant 
and that they wanted to stop, 
but were unable to do so. The 
most common adverse e"ects 
of HMAs include dry mouth, 
tachycardia, diaphoresis, nau-
sea, vomiting, loss of concen-
tration, tremors, and feelings 
of alienation/disassociation.  
Other adverse e"ects include 
panic attacks, agitation, para-
noia, delusions, psychosis, hal-
lucinations, seizures, coronary 
ischemic events, and suicide.   
 
Detection/Treatment
Traditional laboratory assays 
for delta-9-THC do not detect 
synthetic cannabinoids. Liquid 
chromatography and mass 
spectrometry methods have 
sometimes detected speci!c 
metabolites of synthetic can-
nabinoids in blood and urine 
specimens. Encouraging prog-
ress has been made by some 
independent companies that 
have developed commercial 
tests for the detection of syn-
thetic cannabinoids in blood 
and urine. However, these as-
says are limited to testing for 
speci!c metabolites of known 
compounds typically in syn-
thetic cannabinoids. It must 
be stressed that, since there 
are many di"erent possible 
metabolites, depending on the 
synthetic cannabinoid product 
used, it is not currently possible 
to de!nitively rule out synthetic 
cannabinoid use on the basis 
of a negative test result. It is 
not known how long parent 
compounds and its metabolites 
persist in the urine following an 
exposure, but it is estimated to 
range from 48-72 hours.
There is no antidote for syn-
thetic cannabinoid exposures, 
so treatment consists of sup-
portive care. Benzodiazepines 
should be administered to con-
trol agitation, anxiety, tachy-
cardia, and seizures, which 
are all symptoms not typically 
seen with regular marijuana. 
The use of antipsychotic medi-
cations to treat psychosis may 
decrease the seizure thresh-
old, placing the patient at an 
even greater risk of seizures. 
Appropriate patient restraints 
should be used if there is risk 
of harm to self or others. All 
exposed patients should be 
closely observed until abnor-
mal vital signs, vomiting, and 
psychiatric symptoms have 
resolved. 
General Advice  
Health care professionals must 
become aware of the intense 
consequences and adverse 
e"ects that may result from 
the use of designer drugs. It is 
essential that all possible expo-
sures be reported to regional 
poison control centers (800-
222-1222) in order to better 
track and manage the use of 
designer drugs in the U.S. 
Resources




pdf  Drugs of Abuse. 2011 
Edition. A DEA Resource Guide.
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The  EPSDT Care for Kids Newsletter  is published 
three times a year, in print and online, as a joint 
e"ort of the Iowa Prevention of Disabilities Policy 
Council, the Iowa Department of Human Services, 
the Iowa Department of Public Health, and the 
Center for Disabilities and Development, which is 
nationally designated as Iowa’s University Center for 
Excellence on Disabilities. The goal of this newsletter 
is to inform Iowa health care professionals about 
the EPSDT Care for Kids program, to encourage 
them to make use of this important resource, and 
to provide them with information about a wide 
range of developments in the !eld of health care. 
NEWSLETTER STAFF
Executive Editors 
Ellen Link, MD 





University of Iowa Children’s Hospital
Center for Disabilities and Development
University Center for Excellence on Disabilities
100 Hawkins Drive
Iowa City IA 52242-1011
Please send 
correspondence 
concerning content to:  
Ellen Link, MD 
Family Care Center –            
Pediatrics  
University of Iowa 
Children’s Hospital 
01212 PFP     
200 Hawkins Drive    
Iowa City, IA 52242-1083
 
Please send 
change of address 
information to:
Marlene Phipps
University of Iowa         
Children’s Hospital 
Center for Disabilities   
and Development
2295 CDD    
100 Hawkins Drive
Iowa City, IA 52242-1011
If you have questions about billing related to EPSDT Care for Kids services, please call Provider Services: 
1- 800-338-7909 If you have questions about clinical issues and EPSDT Care for Kids services, please 
call 1 - 800-383-3826. Please note:  Due to budget restraints, the EPSDT Care for Kids Newsletter is sent 
to o$ces and organizations, rather than to individuals. The newsletter is also available on line at 
www.iowaepsdt.org/EPSDTNews.  Readers are welcome to photocopy or download material from 
the newsletter to share with others.  If you wish to reproduce material from the newsletter in another 
publication, whether print or electronic, please obtain permission prior to publication by contact-
ing the editor. Please include the following acknowledgment with reprinted material: Reprinted by 
permission of the Iowa EPSDT Care for Kids Newsletter.
What’s in this issue
Screening for Depression in Primary Practice . . . . . . . . . . . . . . . . . . . . .1
Pediatric Lipid Screening Guidelines . . . . . . . . . . . . . . . . . . . . . . . . . . . . .4 
Insert 
     Center for Epidemiological Studies
     Depression Scale for Children (CES-DC) . . . . . . . . . . . . . . . . . . . . . . . .5
     Evidence-based Recommendations
     for Lipid Assessment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .6
Editorial Board
Kay DeGarmo 
Rhonda Enserro, MD 
Royann Mraz, MD 
Sally Nadolsky
Analisa Pearson, RN, BSN 
Steven Wolfe, MD
